ABVC

MKT CAP:$16M

ABVC BioPharma, Inc.

Market Cap

$16M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.14-$1.05 (-47.95%)

Apr 23, 2026

Company Details

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combinati...

CEO

Uttam Yashwant Patil

IPO Date

Nov 10, 2004

Website

www.abvcpharma.com

Key Metrics TTM

Revenue

$1M

+369.8% YoY

Net Income

-$3M

EPS (Diluted)

-$0.19

Free Cash Flow

-$1M

Revenue / Share

$0.05

Gross Margin

100.0%

Operating Margin

-315.7%

Net Margin

-291.5%

FCF Margin

-113.7%

P/S

13.4x

P/E

—

Earnings Reports

Q4 2025

Apr 28, 2026

PENDING

Q3 2025

Oct 31, 2025

$796.0K+104.5%EPS -$0.05

Q2 2025

Aug 13, 2025

$0-100.0%EPS -$0.13

Q4 2024

Apr 15, 2025

$2.0KEPS $0.02

Q3 2024

Nov 14, 2024

$389.3KEPS -$0.02

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 17	$0	$0	-$237.0K
Q4 17	$0	$0	-$352.8K
Q2 21	$31.4K	$30.8K	-$2M
Q3 21	$99.0K	$98.6K	-$2M
Q1 23	$128.3K	$68.0K	-$2M
Q2 23	$6.1K	-$66.9K	-$2M
Q1 24	$1.2K	$928	-$3M
Q2 24	$117.1K	$117.0K	-$860.1K
Q3 24	$389.3K	$389.0K	$49.9K
Q4 24	$2.0K	$2.0K	-$334.2K
Q2 25	$0	$0	-$2M
Q3 25	$796.0K	$796.0K	-$1M

Valuation

Quarter	P/S	P/E
Q1 17	—	—
Q4 17	—	—
Q2 21	—	—
Q3 21	121.6x	—
Q1 23	61.3x	—
Q2 23	59.9x	—
Q1 24	67.6x	—
Q2 24	62.8x	—
Q3 24	30.9x	—
Q4 24	31.1x	—
Q2 25	31.2x	—
Q3 25	13.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 17	-$862.2K	-$862.2K
Q4 17	-$111.5K	-$111.5K
Q2 21	-$1M	-$1M
Q3 21	-$2M	-$2M
Q1 23	-$1M	-$1M
Q2 23	-$899.8K	-$899.8K
Q1 24	-$955.8K	-$955.8K
Q2 24	-$211.4K	-$211.4K
Q3 24	$171.7K	$171.7K
Q4 24	-$493.6K	-$493.6K
Q2 25	-$894.2K	-$894.2K
Q3 25	-$133.3K	-$133.3K

Capital Expenditures

Quarter	CapEx
Q1 17	$0
Q4 17	$0
Q2 21	$0
Q3 21	$17.5K
Q1 23	$0
Q2 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+758.4%
Q2 23	—	+523.6%
Q1 24	-96.2%	+37.4%
Q2 24	+18.3%	-52.8%
Q3 24	+203.5%	-83.3%
Q4 24	-67.8%	-84.7%
Q2 25	-100.0%	-19.2%
Q3 25	+579.5%	+101.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 17	$0	—
Q4 17	$17.4K	—
Q2 21	$475.7K	1513.1%
Q3 21	$225.7K	228.0%
Q1 23	$366.5K	285.7%
Q2 23	$225.7K	3695.2%
Q1 24	$2M	168600.1%
Q2 24	$282.9K	241.5%
Q3 24	$0	0.0%
Q4 24	-$184.3K	-9373.1%
Q2 25	$2M	—
Q3 25	$1M	142.7%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 17	$25.1K	$211.7K	—
Q4 17	$45.7K	—	$307.1K
Q2 21	$358.9K	$2M	—
Q3 21	$263.4K	$2M	—
Q1 23	$335.0K	$2M	—
Q2 23	$514.4K	$2M	—
Q1 24	$69.1K	$3M	—
Q2 24	$40.4K	$944.2K	—
Q3 24	$37.8K	$301.2K	—
Q4 24	$32.0K	$304.1K	—
Q2 25	$33.3K	$2M	—
Q3 25	$29.9K	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$3M	$95.6K	$4M
Q2 22	$4M	$82.8K	$4M
Q3 22	$1M	$77.6K	$1M
Q4 22	$1M	$75.8K	$1M
Q1 23	$1M	$78.0K	$1M
Q2 23	$742.2K	$76.8K	$819.0K
Q3 23	$1M	$68.5K	$1M
Q4 23	$716.8K	$79.3K	$796.1K
Q1 24	$659.0K	$75.9K	$734.9K
Q2 24	$742.8K	$75.7K	$818.5K
Q3 24	$769.9K	$70.8K	$840.7K
Q4 24	$863.8K	$64.7K	$928.6K
Q1 25	$759.6K	$65.1K	$824.6K
Q2 25	$1M	$65.2K	$1M
Q3 25	$192.1K	$65.2K	$257.2K
Q4 25	$681.5K	$64.4K	$745.8K

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 17	1M	—	—
Q4 17	1M	+0.8%	—
Q2 21	2M	+105.7%	—
Q3 21	3M	+10.1%	—
Q1 23	3M	+23.0%	+180.8%
Q2 23	3M	+0.0%	+178.7%
Q1 24	10M	+194.3%	+298.7%
Q2 24	11M	+16.3%	+321.1%
Q3 24	12M	+9.6%	+275.1%
Q4 24	13M	+7.4%	+302.6%
Q2 25	17M	+30.5%	+78.6%
Q3 25	23M	+33.8%	+105.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 17	$0	9
Q4 17	$0	9
Q2 21	$925	34
Q3 21	$2.9K	34
Q1 23	$5.6K	23
Q2 23	$266	23
Q1 24	$63	19
Q2 24	$6.2K	19
Q3 24	$20.5K	19
Q4 24	$66	30
Q2 25	$0	30
Q3 25	$26.5K	30

Revenue / Employee